Riik: Austraalia
keel: inglise
Allikas: Department of Health (Therapeutic Goods Administration)
Von willebrand factor, Quantity: 800 IU; Factor VIII, Quantity: 900 IU; Factor VIII, Quantity: 15 mg
Octapharma Australia Pty Ltd
Factor VIII,Von willebrand factor
Injection, powder for
Excipient Ingredients: calcium chloride dihydrate; glycine; sodium chloride; sucrose; octoxinol 9; tributyl phosphate; sodium citrate dihydrate
Intravenous
1. Von Willebrand disease (VWD): Treatment of bleeding episodes including surgical bleeding in patients with von Willebrand's disease when desmopressin treatment is ineffective or contraindicated. 2. Haemophilia A: Treatment and prophylaxis of bleeding including surgical bleeding in patients with haemophilia A (congenital FVIII deficiency). There are insuffcient data to recommend the use of Wilate in children less than 12 years of age.
Visual Identification: White or pale yellow or friable solid.;
Licence status A
2007-09-26